From Fentanyl Tariffs to the Golden Triangle: How Drug Control Shapes Geopolitics

In February 2025, President Donald Trump signed an executive order imposing tariffs on Chinese goods on the grounds that China had not done enough to stem the supply of illicit synthetic opioids. By tying the tariffs to Beijing’s counternarcotics cooperation, the order moved a problem of chemical regulation, criminal investigation and public health straight into trade negotiations.

The measure reflects a policy judgement by the US government; it is not a finding of responsibility by any court.

Drug control and international politics meet well beyond US–China relations. In Southeast Asia, illicit drug-making networks are entangled with weak border governance. In Afghanistan, a ban on poppy cultivation sharply cut supply — and farmers’ incomes with it.

The common problem is how to fight cross-border crime while dealing with national sovereignty, livelihoods and medical need.

One set of rules, different national priorities

Today’s international drug-control regime rests mainly on three conventions, of 1961, 1971 and 1988. Their aim is not only to prohibit illicit trade but also to keep controlled substances available for medical and scientific use. The 1988 convention went further, establishing a control regime for precursor chemicals and strengthening cross-border cooperation such as extradition and mutual legal assistance.

The system has to be run jointly by customs services, police, courts and health authorities in many different countries. For consumer markets, the focus may be overdose deaths and street supply. For producing or transit regions, it also includes violence by criminal groups, local incomes and demands for enforcement from abroad.

So even governments that agree on fighting drug trafficking need not agree on who bears the main responsibility, how much intelligence to share, or what outside oversight to accept. These differences are the institutional backdrop against which drugs enter diplomatic bargaining.

Fentanyl: a cross-border supply chain, and politically exposed cooperation

Fentanyl shows how hard it is to pin an illicit drug supply chain on a single country of origin. Reuters investigations have found that criminal networks ship raw materials made in China to the United States and Mexico, where illicit fentanyl is then synthesised in clandestine Mexican labs.

That chain involves distinct stages — chemical supply, transport, manufacture and sale — and exporting ingredients, manufacturing the drug and state involvement should not be conflated.

Nor is China the only source. In a 2026 sanctions announcement, the US Treasury alleged cooperation between Indian chemical suppliers, Latin American intermediaries and Mexican drug-making networks. These should be read as Washington’s grounds for sanctions, not as a description of criminal convictions secured against everyone involved.

The ups and downs of US–China counternarcotics cooperation offer a clear case of diplomacy and enforcement pulling on each other. In August 2022, after then-Speaker of the House Nancy Pelosi visited Taiwan, Beijing announced the suspension of bilateral counternarcotics cooperation as one of its countermeasures. After the two leaders met in November 2023, the sides agreed to resume cooperation, and a counternarcotics working group was launched in January 2024.

The episode shows that even where both sides share an interest in stopping illicit drug trade, cooperation can still be hostage to other strategic disputes. It does not, however, show how many drugs a given diplomatic dispute let through, or how many deaths it caused; causal claims of that kind need support from market, enforcement and public-health data.

Tariff pressure: diplomatic leverage and enforcement results are different things

The Trump administration’s 2025 executive order linked the tariffs on Chinese goods to Washington’s assessment of whether China’s counternarcotics action was adequate. Beijing objected, and said in March that year that the US tariffs had damaged bilateral counternarcotics cooperation.

The tariff was adjusted several times. In March 2025 the rate rose from 10% to 20%. After the two leaders met in Busan at the end of October, the United States cut it back to 10% in November, while China pledged to stop shipping designated chemicals to North America and to tighten controls on others.

On 20 February 2026, the US Supreme Court ruled that the International Emergency Economic Powers Act (IEEPA) does not authorise the president to impose tariffs, and the fentanyl-justified duties stopped being collected on 24 February. The replacement tariffs Washington later placed on China no longer cite drugs as their rationale.

Losing its legal basis did not mean the controls Beijing had promised were rolled back. Since 10 November 2025, exports of 13 fentanyl precursors to the United States, Canada and Mexico have required a licence; according to the Associated Press, the list was widened twice more, in May and September 2026, to 18. A licensing regime is still a regulatory commitment, though: whether it reduces the illicit fentanyl reaching North America has to be tested against separate enforcement and public-health data.

As a matter of policy design, a tariff raises the economic cost to push another government into changing its behaviour. But it does not itself carry out seizures, gather evidence, bring prosecutions or trace criminal proceeds. Even when diplomacy produces new regulatory commitments, it remains to be seen whether they are implemented, and whether supply chains simply move elsewhere.

Judging such policies therefore means separating at least two questions: did it win diplomatic concessions, and did it reduce the harm caused by illicit drugs? The two may be related, but one cannot stand in for the other.

Afghanistan and the Golden Triangle: different conditions for supply control

Afghanistan shows that banning production can produce dramatic change in the short term. After the Taliban announced a drug ban in April 2022, the UN Office on Drugs and Crime (UNODC) estimated that poppy cultivation in 2023 fell by about 95% from the year before. But farmers’ total income from selling that year’s opium harvest also fell by about 92%, from roughly $1.3 billion to $110 million.

Cultivation has not returned to pre-ban levels since, but nor has it fallen in a straight line: UNODC estimates it rebounded by about 19% to 12,800 hectares in 2024, then fell again to about 10,200 hectares in 2025.

These figures cannot be read as proof that the ban had no effect, nor are they enough to show the drug problem has been solved. Cultivation area measures one part of production. Whether the ban lasts still depends on whether farmers have other income, and on how illicit trade adapts to the change in supply.

Southeast Asia presents a different picture. Citing a 2026 UNODC regional report, Singapore’s CNA reported that East and Southeast Asia seized about 349 tonnes of methamphetamine in 2025, up 48% on the year before. Much of the production, it noted, comes from Myanmar’s Shan State, long home to criminal networks and non-state armed groups.

But seizures are not total output, nor a complete measure of the market. Rising seizures may reflect tougher enforcement, or expanding supply. Presenting them as a counternarcotics success, or equating them with rising consumption, goes beyond what the data can support.

Public health: control must also protect legitimate medicine

Drug policy has another task that security debates easily obscure: making sure patients get the medicines they need. In its 2025 guideline on controlled-medicines policy, the World Health Organization (WHO) noted that in some regions regulatory and health-system barriers keep people from pain relief and other controlled medicines, while in others weak prescribing and regulatory safeguards have led to dependence and overdose harm.

In June 2026, the WHO announced that, for the first time, it had invited manufacturers to submit medicines for substance use disorders for prequalification assessment, including methadone and buprenorphine for opioid dependence and naloxone for emergency treatment of opioid overdose. The aim is to widen access to quality-assured medicines — not to legalise illicit trafficking.

For international cooperation, this means counternarcotics work is not only about seizing chemicals and tracing money, but also about medical procurement, drug quality and treatment services. If resources go mainly to border interdiction while patients still cannot get treatment, policy results cannot be judged by seizures alone.

Results depend on what is measured

The suspension and resumption of US–China cooperation, the collapse in Afghan cultivation and the steady rise in Southeast Asian seizures each capture one face of drug policy: diplomatic, productive and enforcement. Each matters; none of them, on its own, represents overall success.

A fuller assessment has to look at once at the price and availability of illicit drugs, the finances and violence of criminal groups, overdose deaths, and whether treatment reaches the people who need it.

Drug control can be a tool of diplomatic pressure; it can also be a shared interest that keeps cross-border cooperation alive. Whether the two can coexist depends on whether political commitments turn into sustained enforcement and health outcomes — rather than remaining bargaining chips.